A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.
Mehnert J, Mortazavi A, Stein M, Donadio A, Zelterman D, McDonough J, Rowen E, Hoimes C, Gibney G, Kelly W. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Journal Of Clinical Oncology 2011, 29: 278-278. DOI: 10.1200/jco.2011.29.7_suppl.278.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPR/CRDose reductionOral tyrosine kinase inhibitorECOG PS 0Grade 3/4 neutropeniaHand-foot syndromePhase II trialProgression-free intervalMedian age 64Tyrosine kinase inhibitorsAnti-angiogenic propertiesECOG 0Evaluable diseaseMaintenance SNeutropenic feverNonhematologic toxicityHematologic toxicityMaintenance therapyPrimary endpointSecondary endpointsStable diseaseII trialPS 0